PROTELICA’S PROPRIETARY DRUG DISCOVERY PLATFORM IS PROVIDING HIGHLY TARGET-SPECIFIC PRONECTINS™, A NOVEL CLASS OF POTENTIAL PROTEIN THERAPEUTICS FOR ONCOLOGY AND OTHER APPLICATIONS WITH HIGH UNMET NEED.
Pronectins™ are newly designed “antibody mimics”, based on our proprietary Human Loop Database, Diversity-generating Mutagenesis, Look-Through and Walk-Through Mutagenesis, and a novel human fibronectin scaffold (14Fn3), meant to replace the first generation MAb for a variety of human diseases. Protelica has developed a pipeline of highly specific Pronectins™ that are being tested at the pre-clinical stage for cancer immunotherapy and other diseases where MAb treatment has shown limited efficacy. Pronectins’ size (1/15 of the MAb MW), stability, specificity, lack of immunogenicity and cost of manufacturing make these proprietary single-domain proteins a very promising novel class of protein therapeutics, whether used by themselves or in combination with other protein structures.
Protelica was founded by Dr. Roberto Crea, who has developed innovative protein engineering technologies since his first instrumental involvement with Genentech in 1977 as the first Director of DNA Chemistry and through his 35+ years of entrepreneurial career in Biotech.
863 Mitten Rd., Ste 101 Burlingame, CA 94010 Phone: +1 650 777-5228 email: Info@protelica.com Web: www.protelica.com
